
Chugai’s Enspryng (Satralizumab) Receives Regulatory Approval from FDA for Neuromyelitis Optica Spectrum Disorder
A treatment option with a novel mechanism of action for anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder (NMOSD) approved in the U.S. Enspryng, the first approved […]


